NeuroMetrix to Present at the Marcum Microcap Conference on June 16, 2017
08 6월 2017 - 8:00PM
Business Wire
NeuroMetrix, Inc. (NASDAQ:NURO) today announced
that Shai N. Gozani M.D., Ph.D., President and CEO of
NeuroMetrix, is scheduled to speak at the upcoming 2017 Marcum
Microcap Conference at the Grand Hyatt Hotel in New York
City. Dr. Gozani intends to provide an update on the
Company's business activities including the Quell® Wearable
Pain Relief Technology™.
The NeuroMetrix presentation is scheduled for Friday,
June 16, 2017, at 10:00 a.m. EST. A live audio webcast
will be available on the investor relations section of the
corporate website - http://www.NeuroMetrix.com/. This webcast
will be archived after the live event.
About Quell
Quell is designed for millions of people suffering from chronic
pain. The advanced wearable device is lightweight and can be worn
during the day while active, and at night while sleeping. It has
been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users
reported an improvement in their chronic pain. Quell users can
personalize and manage therapy discreetly via the Quell Relief app.
Quell also offers advanced health tracking relevant to chronic pain
sufferers including pain, sleep, activity, and gait. Quell was the
winner of the 2016 SXSW (South by Southwest) Innovation
Award for Best Wearable Technology. Quell is available at select
healthcare professionals and retailers.
Visit QuellRelief.com for more information.
About Marcum Microcap Conference
The Marcum Microcap Conference was launched in 2012. The event
has become a nationally recognized forum for publicly traded
companies with less than $500 million in market capitalization to
network with fund managers and high net worth investors who focus
on small cap equities. More than 2,000 participants from all
segments of the microcap market participate each year, including
senior management, finance and legal executives, venture and lower
middle-market private equity investors, institutional investors,
directors, investment bankers, buy- and sell-side analysts, and
service providers to the microcap marketplace.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven
healthcare company combining bioelectrical and digital medicine to
address chronic health conditions including chronic pain, sleep
disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain.
Quell is integrated into a digital health platform that helps
patients optimize their therapy and decrease the impact of chronic
pain on their quality of life. The company also markets DPNCheck®,
a rapid point-of-care test for diabetic neuropathy, which is the
most common long-term complication of Type 2 diabetes. The company
maintains an active research effort and has several pipeline
programs. The company is located in Waltham,
Massachusetts and was founded as a spinoff from
the Harvard-MIT Division of Health Sciences and
Technology in 1996. For more information, please
visit NeuroMetrix.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170608005004/en/
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
NeuroMetrix (NASDAQ:NUROW)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
